Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review
Cystic fibrosis-related diabetes (CFRD) is the most common non-pulmonary comorbidity in people with cystic fibrosis (CF). Current guidelines recommend insulin therapy as the treatment of choice for people with CFRD. In the past, obesity and overweight were uncommon in individuals with CF. However, i...
Saved in:
| Main Authors: | Ammar Ahmed, Anvitha Ankireddypalli, Tasma Harindhanavudhi, Antoinette Moran, Amir Moheet |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Clinical & Translational Endocrinology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214623724000462 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Integrated Approaches to Managing Cystic Fibrosis: From Nutritional Optimization to Therapeutic Advancements
by: Salehe Akhondian, et al.
Published: (2024-12-01) -
Effect of CFTR modulators on glucose homeostasis in children and young adults with cystic fibrosis-related diabetes: a systematic review
by: Paola Giordano, et al.
Published: (2025-08-01) -
Cystic Fibrosis and Reproductive Outcomes: The Latest Insights into Fertility and Pregnancy
by: Weronika Małagocka, et al.
Published: (2025-01-01) -
A descriptive cohort study of pregnancy and parenthood in women with cystic fibrosis
by: Aleksandra Duffy, et al.
Published: (2025-07-01) -
Analysis of Ivacaftor drug approval for cystic fibrosis patients with gating mutations.
by: Nemirajaiah, S.
Published: (2021-08-01)